Shuaixiang Zhou

1.1k total citations
24 papers, 725 citations indexed

About

Shuaixiang Zhou is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Shuaixiang Zhou has authored 24 papers receiving a total of 725 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 8 papers in Oncology and 8 papers in Immunology. Recurrent topics in Shuaixiang Zhou's work include Cancer Immunotherapy and Biomarkers (5 papers), Microbial Natural Products and Biosynthesis (4 papers) and CAR-T cell therapy research (4 papers). Shuaixiang Zhou is often cited by papers focused on Cancer Immunotherapy and Biomarkers (5 papers), Microbial Natural Products and Biosynthesis (4 papers) and CAR-T cell therapy research (4 papers). Shuaixiang Zhou collaborates with scholars based in China, Australia and United States. Shuaixiang Zhou's co-authors include Meizhong Luo, Wen Liu, Robert D. Willows, Bingliang Chen, Zhihai Wu, Weiwei Wu, Junjian Liu, Haiqing Ni, Shoufeng Wang and Jing Hua and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Biological Chemistry and PLANT PHYSIOLOGY.

In The Last Decade

Shuaixiang Zhou

22 papers receiving 717 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shuaixiang Zhou China 14 333 217 176 156 109 24 725
Michele Gunsior United States 13 616 1.8× 94 0.4× 140 0.8× 83 0.5× 27 0.2× 26 938
Karin von Schwarzenberg Germany 15 572 1.7× 134 0.6× 158 0.9× 73 0.5× 15 0.1× 24 890
Hiroyuki Kumagai Japan 15 468 1.4× 84 0.4× 40 0.2× 130 0.8× 76 0.7× 47 792
Ayse Batova United States 18 603 1.8× 232 1.1× 81 0.5× 111 0.7× 157 1.4× 28 995
Xiaoping Qian China 19 527 1.6× 324 1.5× 110 0.6× 91 0.6× 67 0.6× 66 991
Bo Lin China 16 521 1.6× 183 0.8× 86 0.5× 33 0.2× 29 0.3× 52 906
Lucia Knopfová Czechia 15 358 1.1× 190 0.9× 100 0.6× 41 0.3× 30 0.3× 41 689
Yoshiyuki Nishikawa Japan 13 468 1.4× 131 0.6× 99 0.6× 19 0.1× 21 0.2× 28 745
Odile Sainte‐Catherine France 15 256 0.8× 229 1.1× 91 0.5× 13 0.1× 68 0.6× 20 696
Vanessa Moreno Spain 10 360 1.1× 120 0.6× 68 0.4× 26 0.2× 32 0.3× 10 668

Countries citing papers authored by Shuaixiang Zhou

Since Specialization
Citations

This map shows the geographic impact of Shuaixiang Zhou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shuaixiang Zhou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shuaixiang Zhou more than expected).

Fields of papers citing papers by Shuaixiang Zhou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shuaixiang Zhou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shuaixiang Zhou. The network helps show where Shuaixiang Zhou may publish in the future.

Co-authorship network of co-authors of Shuaixiang Zhou

This figure shows the co-authorship network connecting the top 25 collaborators of Shuaixiang Zhou. A scholar is included among the top collaborators of Shuaixiang Zhou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shuaixiang Zhou. Shuaixiang Zhou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cao, Lei, Haiqing Ni, Bing Wu, et al.. (2025). A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism. Molecular Cancer Therapeutics. 25(1). 21–33.
2.
Zhang, Zhimin, Li Li, Zhihai Wu, et al.. (2024). Characterization of a novel anti-PVRIG antibody with Fc-competent function that exerts strong antitumor effects via NK activation in preclinical models. Cancer Immunology Immunotherapy. 73(5). 81–81. 2 indexed citations
3.
Guan, Jian, Shuaixiang Zhou, Lei Cao, et al.. (2024). Abstract LB056: IBI334, a novel ADCC-enhanced B7-H3/EGFR bispecific antibody, demonstrated potent pre-clinical efficacy in solid tumors. Cancer Research. 84(7_Supplement). LB056–LB056. 2 indexed citations
4.
Guan, Jian, Xiao Zhang, Weiwei Wu, et al.. (2024). Abstract LB055: IBI3001: A potentially first-in-class site-specifically conjugated B7-H3/EGFR bispecific ADC for multiple solid tumors. Cancer Research. 84(7_Supplement). LB055–LB055. 1 indexed citations
5.
Ni, Haiqing, Mengjia Zhu, Zhihui Kuang, et al.. (2022). IBI379, a novel B cell maturation antigen/CD3 bispecific T-cell engager, displays high antitumor efficacy in preclinical models of multiple myeloma. Cancer Letters. 536. 215663–215663. 2 indexed citations
6.
Zhou, Ying, Haoran Shen, Min Wu, et al.. (2022). Pharmacology, pharmacokinetics, and toxicity characterization of a novel anti-CD73 therapeutic antibody IBI325 for cancer immunotherapy. International Journal of Biological Macromolecules. 229. 158–167. 6 indexed citations
7.
Wang, Yan, Haiqing Ni, Shuaixiang Zhou, et al.. (2020). Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity. Cancer Immunology Immunotherapy. 70(2). 365–376. 87 indexed citations
8.
Li, Li, Zhihai Wu, Min Wu, et al.. (2020). IBI112, a selective anti-IL23p19 monoclonal antibody, displays high efficacy in IL-23-induced psoriasiform dermatitis. International Immunopharmacology. 89(Pt B). 107008–107008. 9 indexed citations
9.
Ni, Haiqing, Yajing Qiu, Jing Hua, et al.. (2020). Abstract 3270: Dual blockade of PD-L1 and LAG-3 using a bispecific antibody improves anti-tumor immunity. Cancer Research. 80(16_Supplement). 3270–3270. 1 indexed citations
10.
11.
Wang, Jie, Jing Hua, Zhihai Wu, et al.. (2019). Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit. mAbs. 11(8). 1443–1451. 97 indexed citations
12.
Qiu, Yanping, Fang Zhang, Rijing Liao, et al.. (2017). Thiolation Protein-Based Transfer of Indolyl to a Ribosomally Synthesized Polythiazolyl Peptide Intermediate during the Biosynthesis of the Side-Ring System of Nosiheptide. Journal of the American Chemical Society. 139(50). 18186–18189. 19 indexed citations
13.
Zhou, Shuaixiang, et al.. (2017). 1-N-histidine phosphorylation of ChlD by the AAA+ ChlI2 stimulates magnesium chelatase activity in chlorophyll synthesis. Biochemical Journal. 474(12). 2095–2105. 14 indexed citations
14.
Lin, Zhi, Jia Ji, Shuaixiang Zhou, et al.. (2017). Processing 2-Methyl-l-Tryptophan through Tandem Transamination and Selective Oxygenation Initiates Indole Ring Expansion in the Biosynthesis of Thiostrepton. Journal of the American Chemical Society. 139(35). 12105–12108. 28 indexed citations
15.
Zhou, Shuaixiang, et al.. (2016). GUN4-Protoporphyrin IX Is a Singlet Oxygen Generator with Consequences for Plastid Retrograde Signaling. Journal of Biological Chemistry. 291(17). 8978–8984. 35 indexed citations
16.
Tian, Zhenhua, Peng Sun, Yan Yan, et al.. (2015). An enzymatic [4+2] cyclization cascade creates the pentacyclic core of pyrroindomycins. Nature Chemical Biology. 11(4). 259–265. 121 indexed citations
17.
Zhou, Shuaixiang, et al.. (2014). Inducing the oxidative stress response in Escherichia coli improves the quality of a recombinant protein: Magnesium chelatase ChlH. Protein Expression and Purification. 101. 61–67. 8 indexed citations
18.
Wang, Shoufeng, Shuaixiang Zhou, & Wen Liu. (2013). Opportunities and challenges from current investigations into the biosynthetic logic of nosiheptide-represented thiopeptide antibiotics. Current Opinion in Chemical Biology. 17(4). 626–634. 38 indexed citations
19.
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michele Gunsior Breakdown of academic impact, for papers by Karin von Schwarzenberg Breakdown of academic impact, for papers by Hiroyuki Kumagai Breakdown of academic impact, for papers by Ayse Batova Breakdown of academic impact, for papers by Xiaoping Qian Breakdown of academic impact, for papers by Bo Lin Breakdown of academic impact, for papers by Lucia Knopfová Breakdown of academic impact, for papers by Yoshiyuki Nishikawa Breakdown of academic impact, for papers by Odile Sainte‐Catherine Breakdown of academic impact, for papers by Vanessa Moreno
Rankless by CCL
2026